Drug information of Aminohippurate Sodium
Aminohippurate Sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated “PAH”.
Mechanism of effect
Undergoes glomerular filtration; ~90% proximal tubular secretion in a single circulation
Used to measure the functional activity of the renal tubular secretory mechanism or transport maximum (TmPAH)
Renal Clearance: ~90% in a single circulation at low plasma concentrations
Renal Function Diagnostic
Used for estimation and measurement of renal function (effective renal plasma flow and tubular secretion)
Goal is to maintain plasma concentration of 2 mg/dL
Load 6-10 mg/kg, infuse at 10-24 mg/min
Side effectsAngioedema , flushing , urticaria
Patients have sensations of warmth or desire to defecate or urinate during or after infusion
- Angioedema, flushing, vasomotor disturbances
- Nausea, vomiting & cramps
InteractionsAcyclovir , Ibuprofen , Indomethacin , Piroxicam , Tolmetin , Diclofenac , cefprozil , ceftibuten , etodolac , Sulfamethoxazole , Methyclothiazide , mesalamine , cyclopenthiazide , cefpirome , Cefamandole , SULFISOXAZOLE , Lornoxicam , Meclofenamate , Nabumetone , Oxaprozin , Aceclofenac , Celecoxib , Acemetacin , Sulindac , Bendroflumethiazide , Balsalazide , fenoprofen , Salsalate , Diflunisal , Tolfenamic Acid , Parecoxib , Chlorthalidone , Valcyte (valganciclovir) , Indapamide , flurbiprofen , chlorpropamide , Cefadroxil , Ketoprofen , Ketorolac , Ganciclovir , probenecid , Aspirin , cefepime , Chlorothiazide , Mycophenolate mofetil , Methotrexate , Metolazone , Mefenamic acid , Meloxicam , Hydrochlorothiazide , Cefalexin , Ceftazidime , Cefotaxime , Sulfadiazine , Sulfasalazine , valganciclovir
-Low cardiac reserve
-Latex sensitive individuals: Vial stopper contains dry natural latex
-Administer IV solutions with caution to patients with low cardiac reserve (rapid increase in plasma volume may precipitate congestive heart failure
Points of recommendation
-Your doctor will check your progress closely while you are receiving aminohippurate sodium.
-The vial stopper of aminohippurate sodium contains dry natural rubber (a derivative of latex), which may cause allergic reactions in people who are sensitive to latex. Tell your doctor if you have a latex allergy before you receive aminohippurate sodium.
-Do not take other medicines unless they have been discussed with your doctor.
Animal reproduction studies have not been done with PAH. It is also not known whether PAH can cause fetal harm when given to a pregnant woman or can affect reproduction capacity. PAH should be given to a pregnant woman only if clearly needed.
Breast feeding warning
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when PAH is administered to a nursing woman.